nova bio-pharma technologies limited
nova bio-pharma technologies limited Company Information
Company Number
06936355
Next Accounts
Dec 2025
Shareholders
nova bio-pharma holdings ltd
Group Structure
View All
Industry
Manufacture of basic pharmaceutical products
Registered Address
martin house, gloucester crescent, wigston, leicestershire, LE18 4YL
Website
http://midastech.co.uknova bio-pharma technologies limited Estimated Valuation
Pomanda estimates the enterprise value of NOVA BIO-PHARMA TECHNOLOGIES LIMITED at £1.2m based on a Turnover of £940.2k and 1.3x industry multiple (adjusted for size and gross margin).
nova bio-pharma technologies limited Estimated Valuation
Pomanda estimates the enterprise value of NOVA BIO-PHARMA TECHNOLOGIES LIMITED at £0 based on an EBITDA of £-391.3k and a 5.46x industry multiple (adjusted for size and gross margin).
nova bio-pharma technologies limited Estimated Valuation
Pomanda estimates the enterprise value of NOVA BIO-PHARMA TECHNOLOGIES LIMITED at £0 based on Net Assets of £-569.7k and 1.78x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Nova Bio-pharma Technologies Limited Overview
Nova Bio-pharma Technologies Limited is a live company located in wigston, LE18 4YL with a Companies House number of 06936355. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in June 2009, it's largest shareholder is nova bio-pharma holdings ltd with a 100% stake. Nova Bio-pharma Technologies Limited is a established, small sized company, Pomanda has estimated its turnover at £940.2k with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Nova Bio-pharma Technologies Limited Health Check
Pomanda's financial health check has awarded Nova Bio-Pharma Technologies Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 7 areas for improvement. Company Health Check FAQs
1 Strong
2 Regular
7 Weak
Size
annual sales of £940.2k, make it smaller than the average company (£35.2m)
- Nova Bio-pharma Technologies Limited
£35.2m - Industry AVG
Growth
3 year (CAGR) sales growth of 79%, show it is growing at a faster rate (5.5%)
- Nova Bio-pharma Technologies Limited
5.5% - Industry AVG
Production
with a gross margin of 35.6%, this company has a comparable cost of product (35.6%)
- Nova Bio-pharma Technologies Limited
35.6% - Industry AVG
Profitability
an operating margin of -42.3% make it less profitable than the average company (7.4%)
- Nova Bio-pharma Technologies Limited
7.4% - Industry AVG
Employees
with 4 employees, this is below the industry average (114)
4 - Nova Bio-pharma Technologies Limited
114 - Industry AVG
Pay Structure
on an average salary of £63.2k, the company has an equivalent pay structure (£63.2k)
- Nova Bio-pharma Technologies Limited
£63.2k - Industry AVG
Efficiency
resulting in sales per employee of £235.1k, this is less efficient (£407.1k)
- Nova Bio-pharma Technologies Limited
£407.1k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Nova Bio-pharma Technologies Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 7 days, this is quicker than average (32 days)
- Nova Bio-pharma Technologies Limited
32 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Nova Bio-pharma Technologies Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (9 weeks)
0 weeks - Nova Bio-pharma Technologies Limited
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 148.7%, this is a higher level of debt than the average (39.7%)
148.7% - Nova Bio-pharma Technologies Limited
39.7% - Industry AVG
NOVA BIO-PHARMA TECHNOLOGIES LIMITED financials
Nova Bio-Pharma Technologies Limited's latest turnover from March 2024 is estimated at £940.2 thousand and the company has net assets of -£569.7 thousand. According to their latest financial statements, Nova Bio-Pharma Technologies Limited has 4 employees and maintains cash reserves of £22.7 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 241,232 | 164,569 | 129,816 | 247,545 | 182,169 | 29,306 | 62,641 | 170,825 | 219,599 | 212,241 | 90,710 | ||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 5,887 | 14,190 | 9,212 | 17,328 | 6,692 | 36,155 | 3,080 | 222 | |||||||
| Gross Profit | 235,345 | 150,379 | 120,604 | 230,217 | 175,477 | -6,849 | 59,561 | 170,603 | 219,599 | ||||||
| Admin Expenses | 501,605 | 441,739 | 346,527 | ||||||||||||
| Operating Profit | -266,260 | -291,360 | -126,928 | -89,696 | -256,204 | -336,022 | -184,480 | ||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | -266,260 | -291,360 | -252,299 | -134,490 | -70,412 | -10,499 | -161,528 | -158,079 | -126,928 | -89,696 | -256,204 | -336,022 | -184,480 | ||
| Tax | 84,943 | 73,867 | 45,033 | 56,302 | 9,599 | 29,377 | 17,847 | 42,984 | |||||||
| Profit After Tax | -181,317 | -217,493 | -207,266 | -78,188 | -60,813 | 18,878 | -143,681 | -115,095 | -126,928 | -89,696 | -256,204 | -336,022 | -184,480 | ||
| Dividends Paid | |||||||||||||||
| Retained Profit | -181,317 | -217,493 | -207,266 | -78,188 | -60,813 | 18,878 | -143,681 | -115,095 | -126,928 | -89,696 | -256,204 | -336,022 | -184,480 | ||
| Employee Costs | 251,368 | 251,860 | 214,961 | 202,168 | 180,930 | 132,400 | 153,273 | 136,595 | 127,353 | 90,126 | 112,055 | 87,816 | 18,830 | ||
| Number Of Employees | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 4 | 7 | 7 | 6 | 6 | 6 | 1 |
| EBITDA* | -250,127 | -270,686 | -6,928 | 30,304 | -136,204 | -216,022 | -144,480 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 13,301 | 10,867 | 19,885 | 31,957 | 43,505 | 55,024 | 57,879 | 45,579 | 12,500 | 13,666 | |||||
| Intangible Assets | 100,000 | 220,000 | 340,000 | 460,000 | 580,000 | ||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | 90,548 | 52,259 | 100 | 100 | 100 | 100 | |||||||||
| Total Fixed Assets | 13,301 | 10,867 | 19,885 | 31,957 | 43,505 | 55,024 | 57,879 | 45,579 | 12,500 | 104,214 | 152,259 | 220,100 | 340,100 | 460,100 | 580,100 |
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 88,000 | ||||||||||||||
| Group Debtors | 1,129,754 | 1,039,278 | 1,106,988 | 1,023,203 | 1,008,799 | 102,780 | 93,641 | 81,681 | 48,423 | 60,975 | |||||
| Misc Debtors | 3,273 | 3,837 | 2,984 | 5,028 | 4,047 | 641 | 9,251 | 169,164 | 735 | 5,435 | 7,769 | 7,341 | 6,632 | 2,093 | 15,381 |
| Cash | 22,729 | 30,209 | 93,863 | 188,675 | 207,767 | 281,308 | 365,980 | 93,030 | 54,888 | 46,388 | 7,064 | 28,602 | 88,414 | 50,348 | 159,001 |
| misc current assets | |||||||||||||||
| total current assets | 1,155,756 | 1,073,324 | 1,203,835 | 1,216,906 | 1,220,613 | 384,729 | 468,872 | 343,875 | 104,046 | 112,798 | 14,833 | 123,943 | 95,046 | 52,441 | 174,382 |
| total assets | 1,169,057 | 1,084,191 | 1,223,720 | 1,248,863 | 1,264,118 | 439,753 | 526,751 | 389,454 | 116,546 | 217,012 | 167,092 | 344,043 | 435,146 | 512,541 | 754,482 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 12,826 | 1,504 | 3,051 | 17,244 | 17,415 | 7,917 | 5,997 | 3,320 | 23,047 | 8,222 | 15,342 | 19,154 | 13,368 | 16,725 | |
| Group/Directors Accounts | 1,701,080 | 1,223,559 | 818,939 | 646,582 | 451,282 | 934,149 | 917,126 | 715,444 | 509,463 | 449,900 | |||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 22,035 | 30,286 | 25,756 | 26,588 | 17,446 | 21,668 | 37,001 | 44,854 | 5,404 | 2,199 | 2,200 | 2,000 | 2,000 | 1,550 | 2,000 |
| total current liabilities | 1,735,941 | 1,255,349 | 847,746 | 690,414 | 486,143 | 955,817 | 962,044 | 766,295 | 518,187 | 475,146 | 10,422 | 17,342 | 21,154 | 14,918 | 18,725 |
| loans | 299,900 | 343,003 | 340,598 | 168,025 | 70,137 | ||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | 2,793 | 2,067 | 4,179 | 5,337 | 7,370 | 6,065 | 8,648 | 6,287 | 365 | 191 | |||||
| total long term liabilities | 2,793 | 2,067 | 4,179 | 5,337 | 7,370 | 6,065 | 8,648 | 6,287 | 365 | 191 | 299,900 | 343,003 | 340,598 | 168,025 | 70,137 |
| total liabilities | 1,738,734 | 1,257,416 | 851,925 | 695,751 | 493,513 | 961,882 | 970,692 | 772,582 | 518,552 | 475,337 | 310,322 | 360,345 | 361,752 | 182,943 | 88,862 |
| net assets | -569,677 | -173,225 | 371,795 | 553,112 | 770,605 | -522,129 | -443,941 | -383,128 | -402,006 | -258,325 | -143,230 | -16,302 | 73,394 | 329,598 | 665,620 |
| total shareholders funds | -569,677 | -173,225 | 371,795 | 553,112 | 770,605 | -522,129 | -443,941 | -383,128 | -402,006 | -258,325 | -143,230 | -16,302 | 73,394 | 329,598 | 665,620 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -266,260 | -291,360 | -126,928 | -89,696 | -256,204 | -336,022 | -184,480 | ||||||||
| Depreciation | 6,587 | 9,018 | 16,133 | 20,674 | 20,019 | 19,444 | 16,199 | 8,475 | 3,535 | 1,838 | 20,000 | ||||
| Amortisation | 100,000 | 120,000 | 120,000 | 120,000 | 120,000 | 20,000 | |||||||||
| Tax | 84,943 | 73,867 | 45,033 | 56,302 | 9,599 | 29,377 | 17,847 | 42,984 | |||||||
| Stock | |||||||||||||||
| Debtors | 89,912 | -66,857 | 81,741 | 15,385 | 909,425 | 529 | -147,953 | 201,687 | -107,800 | 96,930 | -35,413 | 88,709 | 4,539 | -13,288 | 15,481 |
| Creditors | 11,322 | -1,547 | -14,193 | -171 | 17,415 | -7,917 | 1,920 | 2,677 | -19,727 | 14,825 | -7,120 | -3,812 | 5,786 | -3,357 | 16,725 |
| Accruals and Deferred Income | -8,251 | 4,530 | -832 | 9,142 | -4,222 | -15,333 | -7,853 | 39,450 | 3,205 | -1 | 200 | 450 | -450 | 2,000 | |
| Deferred Taxes & Provisions | 726 | -2,112 | -1,158 | -2,033 | 1,305 | -2,583 | 2,361 | 5,922 | 174 | 191 | |||||
| Cash flow from operations | -263,108 | -205,266 | 21,565 | -62,217 | -134,507 | -206,541 | -141,236 | ||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | 477,521 | 404,620 | 172,357 | 195,300 | -482,867 | 17,023 | 201,682 | 205,981 | 59,563 | 449,900 | |||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | -299,900 | -43,103 | 2,405 | 172,573 | 97,888 | 70,137 | |||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | 172,357 | 195,300 | 1,017,133 | 17,023 | 201,682 | 205,981 | 59,563 | 150,000 | -43,103 | 2,405 | 172,573 | 97,888 | 920,237 | ||
| cash and cash equivalents | |||||||||||||||
| cash | -7,480 | -63,654 | -94,812 | -19,092 | -73,541 | -84,672 | 272,950 | 38,142 | 8,500 | 39,324 | -21,538 | -59,812 | 38,066 | -108,653 | 159,001 |
| overdraft | |||||||||||||||
| change in cash | -7,480 | -63,654 | -94,812 | -19,092 | -73,541 | -84,672 | 272,950 | 38,142 | 8,500 | 39,324 | -21,538 | -59,812 | 38,066 | -108,653 | 159,001 |
nova bio-pharma technologies limited Credit Report and Business Information
Nova Bio-pharma Technologies Limited Competitor Analysis
Perform a competitor analysis for nova bio-pharma technologies limited by selecting its closest rivals, whether from the MANUFACTURING sector, other small companies, companies in LE18 area or any other competitors across 12 key performance metrics.
nova bio-pharma technologies limited Ownership
NOVA BIO-PHARMA TECHNOLOGIES LIMITED group structure
Nova Bio-Pharma Technologies Limited has no subsidiary companies.
Ultimate parent company
1 parent
NOVA BIO-PHARMA TECHNOLOGIES LIMITED
06936355
nova bio-pharma technologies limited directors
Nova Bio-Pharma Technologies Limited currently has 3 directors. The longest serving directors include Dr Peter White (Jun 2009) and Mr Samooh De Costa (Oct 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Peter White | England | 76 years | Jun 2009 | - | Director |
| Mr Samooh De Costa | England | 50 years | Oct 2017 | - | Director |
| Dr James White | England | 39 years | Oct 2020 | - | Director |
P&L
March 2024turnover
940.2k
+21%
operating profit
-397.8k
0%
gross margin
35.6%
-4.34%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
-569.7k
+2.29%
total assets
1.2m
+0.08%
cash
22.7k
-0.25%
net assets
Total assets minus all liabilities
nova bio-pharma technologies limited company details
company number
06936355
Type
Private limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
incorporation date
June 2009
age
16
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
MOORE
address
martin house, gloucester crescent, wigston, leicestershire, LE18 4YL
Bank
HSBC BANK PLC
Legal Advisor
-
nova bio-pharma technologies limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to nova bio-pharma technologies limited. Currently there are 2 open charges and 1 have been satisfied in the past.
nova bio-pharma technologies limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for NOVA BIO-PHARMA TECHNOLOGIES LIMITED. This can take several minutes, an email will notify you when this has completed.
nova bio-pharma technologies limited Companies House Filings - See Documents
| date | description | view/download |
|---|
